Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Taysha Gene Therapies (TSHA) Stock Price & Analysis
816 Followers
TSHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.62 - $4.32
Previous Close$2.07
Volume1.84M
Average Volume (3M)2.79M
Market Cap
$416.86M
Enterprise Value$351.87M
Total Cash (Recent Filing)$124.00M
Total Debt (Recent Filing)$59.01M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 12, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding187,018,275
10 Day Avg. Volume3,496,925
30 Day Avg. Volume2,788,669
Standard Deviation0.63
R-Squared0.00140
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)10.28
Price to Sales (P/S)35.83
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.85
Enterprise Value/Gross Profit22.77
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$6.72Price Target Upside224.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Taysha Gene Therapies News
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe $2.5B Rett syndrome opportunity is not yet on the radar for many investors.
Potential For ApprovalConfidence in potential approval for TSHA-102 is driven by initial Ph 1/2 safety data from adult/adolescent and pediatric trials, validated safety with no signs of toxic MeCP2 overexpression.
Safety And EfficacyEarly data from low-dose adult and pediatric Ph 1/2 REVEAL trials showed robust safety, promising signs of efficacy.
Bears Say
Clinical DataChallenges in understanding TSHA's pediatric data arise due to numerous formal endpoints, varied clinical observations, patient heterogeneity, and a small sample size.
Investor FocusInvestors may be overly focused on specific clinical measures that were not designed to assess broad-based changes in disease improvement.
Patient ImpactSteroids can cause agitation, potentially having a negative impact on patients.
---
Ownership Overview
20.48% Insiders
12.01% Mutual Funds
55.83% Other Institutional Investors
11.68% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $0.62 and its highest was $4.32 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Currently, no data Available
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is Aug 12, 2024 which is in 36 days.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on May 14, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.007.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -$0.16.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 201,379,400 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went up 21.012%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Among the largest hedge funds holding Taysha Gene Therapies’s share is RA Capital Management. It holds Taysha Gene Therapies’s shares valued at 31M.
---
Taysha Gene Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.72 (224.64% Upside)
$6.72 (224.64% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 7.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.93%
12-Months-Change
Fundamentals
Return on Equity
-606.69%
Trailing 12-Months
Asset Growth
50.59%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
---
TSHA Earnings Call
Q1 2024
0:00 / 0:00
---
TSHA Stock 12 Month Forecast
Average Price Target
$6.72
▲(224.64% Upside)
Technical Analysis
Best Analysts Covering TSHA
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
+34.21%
reiterated a buy rating 2 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +34.21% per trade.
---